We are live on ! Find out more

CMPS

Compass Pathways

CMPS

Market cap $2.01B

14.54 USD

+0.19

1.32%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

14.54

0.00

0%

1 day

1.32%

5 days

9.49%

1 month

8.1%

3 months

23.32%

6 months

130.43%

Year to date

121.98%

1 year

182.88%

5 years

-54.39%

10 years

-49.86%

About: Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.

Employees: 156

Healthcare Medical Care Facilities

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40%

Neutral 60%

Negative 0%

Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

ATLANTA--(BUSINESS WIRE)--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360, Compass' investigational psilocybin treatment, if approved. Strata's founders worked with Compass on the development of the provider traini.

Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare provider training grant program.

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring.

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

Compass Pathways to Participate in Investor Conferences the Week of September 14th

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global Investment Conference – New York, NY: Fireside chat at 3:30pm ET on September 15, 2026 Morgan Stanley 24th Annual Global Healthcare Conference – New York, NY: Fireside chat.

Compass Pathways to Participate in Investor Conferences the Week of September 14th

Compass Pathways Forecast: Breakout Could Target $22.51–$25.51

CMPS is testing a breakout after positive Phase 3 data, with a close above $15.40 potentially opening the way toward $22.51–$25.51.

Compass Pathways Forecast: Breakout Could Target $22.51–$25.51

Proactive Investors

Compass Pathways stock rises as 52-week data show lasting depression relief

Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral psilocybin treatment for treatment-resistant depression (TRD). The data, from the open-label Part C portion of Study '005, showed sustained efficacy with an infrequent dosing paradigm of two to four times per year.

Compass Pathways stock rises as 52-week data show lasting depression relief

Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the topline 52-week results (Part C) from its Phase 3 COMP005 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which further support COMP360's differentiated profile and potential for long lasting benefit. The open-label Part C data demonst.

Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at Psych Congress 2026, taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data examining the burden of TRD alongside encore presentations from its COMP360.

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees. The equity awards were granted on September 1, 2026 and consisted of options to purchase an aggregate of 280,600 shares and restricted share units or, in the case o.

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. Compass is leading a profound shift in the development of new t.

Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree

See News Rankings

Price charts implemented using Lightweight Charts™